Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial

BACKGROUND: In the 24-month MS-STAT phase 2 trial, we showed that high-dose simvastatin significantly reduced the annualised rate of whole brain atrophy in patients with secondary progressive multiple sclerosis (SPMS). We now describe the results of the MS-STAT cognitive substudy, in which we invest...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Dennis, Binks, Sophie, Nicholas, Jennifer M, Frost, Chris, Cardoso, M Jorge, Ourselin, Sebastien, Wilkie, David, Nicholas, Richard, Chataway, Jeremy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507768/
https://www.ncbi.nlm.nih.gov/pubmed/28600189
http://dx.doi.org/10.1016/S1474-4422(17)30113-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507768/
https://www.ncbi.nlm.nih.gov/pubmed/28600189
http://dx.doi.org/10.1016/S1474-4422(17)30113-8

Ejemplares similares